Article Details

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Retrieved on: 2024-10-10 20:19:42

Tags for this article:

Click the tags to see associated articles and topics

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers. View article details on hiswai:

Excerpt

... . AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been identi.

Article found on: quantisnow.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo